Thyroid hormone receptor alpha

<p>Provides any useful information about the protein, mostly biological knowledge.</p><p><a href='../manual/function_section' target='_top'>More...</a></p>Functionⁱ

Sites

Feature key	Position(s)	Length	Description	Graphical view	Feature identifier	Actions
<p>Describes the interaction between a single amino acid and another chemical entity. Priority is given to the annotation of physiological ligands.</p><p><a href='../manual/binding' target='_top'>More...</a></p>Binding sitei	228 – 228	1	Thyroid hormone
<p>Describes the interaction between a single amino acid and another chemical entity. Priority is given to the annotation of physiological ligands.</p><p><a href='../manual/binding' target='_top'>More...</a></p>Binding sitei	277 – 277	1	Thyroid hormone; via amide nitrogen

Regions

Feature key	Position(s)	Length	Description	Graphical view	Feature identifier	Actions
<p>Specifies the position and type of each <span class="caps">DNA</span>-binding domain present within the protein.</p><p><a href='../manual/dna_bind' target='_top'>More...</a></p>DNA bindingi	53 – 127	75	Nuclear receptorPROSITE-ProRule annotation <p>Manual validated information which has been generated by the UniProtKB automatic annotation system.</p> <p><a href="/manual/evidences#ECO:0000255">More…</a></p> Manual assertion according to rulesi PROSITE-ProRule:PRU00407			Add BLAST
<p>Specifies the position(s) and type(s) of zinc fingers within the protein.</p><p><a href='../manual/zn_fing' target='_top'>More...</a></p>Zinc fingeri	53 – 73	21	NR C4-typePROSITE-ProRule annotation <p>Manual validated information which has been generated by the UniProtKB automatic annotation system.</p> <p><a href="/manual/evidences#ECO:0000255">More…</a></p> Manual assertion according to rulesi PROSITE-ProRule:PRU00407			Add BLAST
<p>Specifies the position(s) and type(s) of zinc fingers within the protein.</p><p><a href='../manual/zn_fing' target='_top'>More...</a></p>Zinc fingeri	91 – 115	25	NR C4-typePROSITE-ProRule annotation <p>Manual validated information which has been generated by the UniProtKB automatic annotation system.</p> <p><a href="/manual/evidences#ECO:0000255">More…</a></p> Manual assertion according to rulesi PROSITE-ProRule:PRU00407			Add BLAST

<p>The <a href="http://www.geneontology.org/">Gene Ontology (GO)</a> project provides a set of hierarchical controlled vocabulary split into 3 categories:</p><p><a href='../manual/gene_ontology' target='_top'>More...</a></p>GO - Molecular functionⁱ

• chromatin DNA binding Source: Ensembl
• intronic transcription regulatory region DNA binding Source: Ensembl
• protein domain specific binding Source: UniProtKB

  <p>Inferred from Physical Interaction</p> <p>Covers physical interactions between the gene product of interest and another molecule (or ion, or complex).</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#ipi">GO evidence code guide</a></p> Inferred from physical interactionⁱ

  • 9653119

• steroid hormone receptor activity Source: InterPro
• steroid receptor RNA activator RNA binding Source: Ensembl
• TBP-class protein binding Source: UniProtKB

  <p>Inferred from Direct Assay</p> <p>Used to indicate a direct assay for the function, process or component indicated by the GO term.</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#ida">GO evidence code guide</a></p> Inferred from direct assayⁱ

  • 8524305

• thyroid hormone binding Source: UniProtKB

  <p>Inferred from Direct Assay</p> <p>Used to indicate a direct assay for the function, process or component indicated by the GO term.</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#ida">GO evidence code guide</a></p> Inferred from direct assayⁱ

  • 15466465
  • 8710870

• thyroid hormone receptor activity Source: UniProtKB

  <p>Inferred from Direct Assay</p> <p>Used to indicate a direct assay for the function, process or component indicated by the GO term.</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#ida">GO evidence code guide</a></p> Inferred from direct assayⁱ

  • 15466465
  • 8710870

• transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding Source: Ensembl
• transcription factor activity, sequence-specific DNA binding Source: UniProtKB

  <p>Inferred from Direct Assay</p> <p>Used to indicate a direct assay for the function, process or component indicated by the GO term.</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#ida">GO evidence code guide</a></p> Inferred from direct assayⁱ

  • 8710870
  • 9653119

• transcription factor binding Source: UniProtKB

  <p>Inferred from Physical Interaction</p> <p>Covers physical interactions between the gene product of interest and another molecule (or ion, or complex).</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#ipi">GO evidence code guide</a></p> Inferred from physical interactionⁱ

  • 8524305

• transcription regulatory region DNA binding Source: BHF-UCL

  <p>Inferred from Direct Assay</p> <p>Used to indicate a direct assay for the function, process or component indicated by the GO term.</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#ida">GO evidence code guide</a></p> Inferred from direct assayⁱ

  • 18052923

• transcription regulatory region sequence-specific DNA binding Source: Ensembl
• zinc ion binding Source: InterPro

<p>The <a href="http://www.geneontology.org/">Gene Ontology (GO)</a> project provides a set of hierarchical controlled vocabulary split into 3 categories:</p><p><a href='../manual/gene_ontology' target='_top'>More...</a></p>GO - Biological processⁱ

• adrenal gland development Source: Ensembl
• brain development Source: Ensembl
• cartilage condensation Source: Ensembl
• cytoplasmic sequestering of transcription factor Source: Ensembl
• digestive tract development Source: Ensembl
• embryonic organ development Source: Ensembl
• erythrocyte differentiation Source: Ensembl
• female courtship behavior Source: Ensembl
• hormone-mediated signaling pathway Source: BHF-UCL

  <p>Inferred from Direct Assay</p> <p>Used to indicate a direct assay for the function, process or component indicated by the GO term.</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#ida">GO evidence code guide</a></p> Inferred from direct assayⁱ

  • 18052923

• kidney development Source: Ensembl
• learning or memory Source: Ensembl
• liver development Source: Ensembl
• negative regulation of DNA-templated transcription, initiation Source: UniProtKB

  <p>Inferred from Direct Assay</p> <p>Used to indicate a direct assay for the function, process or component indicated by the GO term.</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#ida">GO evidence code guide</a></p> Inferred from direct assayⁱ

  • 8524305

• negative regulation of RNA polymerase II transcriptional preinitiation complex assembly Source: UniProtKB

  <p>Inferred from Direct Assay</p> <p>Used to indicate a direct assay for the function, process or component indicated by the GO term.</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#ida">GO evidence code guide</a></p> Inferred from direct assayⁱ

  • 8524305

• negative regulation of sequence-specific DNA binding transcription factor activity Source: Ensembl
• negative regulation of transcription, DNA-templated Source: UniProtKB

  <p>Inferred from Direct Assay</p> <p>Used to indicate a direct assay for the function, process or component indicated by the GO term.</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#ida">GO evidence code guide</a></p> Inferred from direct assayⁱ

  • 8710870

• ossification Source: Ensembl
• positive regulation of female receptivity Source: Ensembl
• positive regulation of myotube differentiation Source: Ensembl
• positive regulation of transcription from RNA polymerase II promoter Source: Ensembl
• regulation of heart contraction Source: Ensembl
• regulation of lipid catabolic process Source: Ensembl
• regulation of myeloid cell apoptotic process Source: Ensembl
• regulation of thyroid hormone mediated signaling pathway Source: Ensembl
• regulation of transcription from RNA polymerase II promoter Source: BHF-UCL

  <p>Inferred from Direct Assay</p> <p>Used to indicate a direct assay for the function, process or component indicated by the GO term.</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#ida">GO evidence code guide</a></p> Inferred from direct assayⁱ

  • 18052923

• response to cold Source: Ensembl
• response to drug Source: Ensembl
• response to nutrient levels Source: Ensembl
• thyroid gland development Source: Ensembl
• transcription from RNA polymerase II promoter Source: UniProtKB

  <p>Inferred from Direct Assay</p> <p>Used to indicate a direct assay for the function, process or component indicated by the GO term.</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#ida">GO evidence code guide</a></p> Inferred from direct assayⁱ

  • 8710870
  • 9653119

• transcription initiation from RNA polymerase II promoter Source: Reactome
• Type I pneumocyte differentiation Source: Ensembl

<p>UniProtKB Keywords constitute a <a target="_top" href="/keywords">controlled vocabulary</a> with a hierarchical structure. Keywords summarise the content of a UniProtKB entry and facilitate the search for proteins of interest.<p><a href='/help/keywords' target='_top'>More...</a></p>Keywords - Molecular functionⁱ

<p>UniProtKB Keywords constitute a <a target="_top" href="/keywords">controlled vocabulary</a> with a hierarchical structure. Keywords summarise the content of a UniProtKB entry and facilitate the search for proteins of interest.<p><a href='/help/keywords' target='_top'>More...</a></p>Keywords - Biological processⁱ

<p>UniProtKB Keywords constitute a <a target="_top" href="/keywords">controlled vocabulary</a> with a hierarchical structure. Keywords summarise the content of a UniProtKB entry and facilitate the search for proteins of interest.<p><a href='/help/keywords' target='_top'>More...</a></p>Keywords - Ligandⁱ

Enzyme and pathway databases

<p>Provides information about the protein and gene name(s) and synonym(s) and about the organism that is the source of the protein sequence.</p><p><a href='../manual/names_and_taxonomy_section' target='_top'>More...</a></p>Names & Taxonomyⁱ

Organism-specific databases

<p>Provides information on the location and the topology of the mature protein in the cell.</p><p><a href='../manual/subcellular_location_section' target='_top'>More...</a></p>Subcellular locationⁱ

<p>The <a href="http://www.geneontology.org/">Gene Ontology (GO)</a> project provides a set of hierarchical controlled vocabulary split into 3 categories:</p><p><a href='../manual/gene_ontology' target='_top'>More...</a></p>GO - Cellular componentⁱ

• cytosol Source: UniProtKB

  <p>Inferred from Direct Assay</p> <p>Used to indicate a direct assay for the function, process or component indicated by the GO term.</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#ida">GO evidence code guide</a></p> Inferred from direct assayⁱ

  • 19158403

• mitochondrion Source: Ensembl
• nucleoplasm Source: Reactome
• nucleus Source: UniProtKB

  <p>Inferred from Direct Assay</p> <p>Used to indicate a direct assay for the function, process or component indicated by the GO term.</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#ida">GO evidence code guide</a></p> Inferred from direct assayⁱ

  • 19158403
  • 8710870

<p>UniProtKB Keywords constitute a <a target="_top" href="/keywords">controlled vocabulary</a> with a hierarchical structure. Keywords summarise the content of a UniProtKB entry and facilitate the search for proteins of interest.<p><a href='/help/keywords' target='_top'>More...</a></p>Keywords - Cellular componentⁱ

<p>Provides information on the disease(s) and phenotype(s) associated with a protein.</p><p><a href='../manual/pathology_and_biotech_section' target='_top'>More...</a></p>Pathology & Biotechⁱ

<p>Provides information on the disease(s) associated with genetic variations in a given protein. The information is extracted from the scientific literature and diseases that are also described in the <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim"><span class="caps">OMIM</span></a> database are represented with a <a href="/diseases">controlled vocabulary</a> in the following way:</p><p><a href='../manual/involvement_in_disease' target='_top'>More...</a></p>Involvement in diseaseⁱ

Hypothyroidism, congenital, non-goitrous, 6 (CHNG6)4 Publications

<p>Manually curated information for which there is published experimental evidence.</p> <p><a href="/manual/evidences#ECO:0000269">More…</a></p> Manual assertion based on experiment inⁱ

• Ref.18

  "A mutation in the thyroid hormone receptor alpha gene."
  Bochukova E., Schoenmakers N., Agostini M., Schoenmakers E., Rajanayagam O., Keogh J.M., Henning E., Reinemund J., Gevers E., Sarri M., Downes K., Offiah A., Albanese A., Halsall D., Schwabe J.W., Bain M., Lindley K., Muntoni F.

  , Khadem F.V., Dattani M., Farooqi I.S., Gurnell M., Chatterjee K.
  N. Engl. J. Med. 366:243-249(2012) [PubMed] [Europe PMC] [Abstract]

  Cited for: INVOLVEMENT IN CHNG6.
• Ref.23

  "Resistance to thyroid hormone caused by a mutation in thyroid hormone receptor (TR)alpha1 and TRalpha2: clinical, biochemical, and genetic analyses of three related patients."
  Moran C., Agostini M., Visser W.E., Schoenmakers E., Schoenmakers N., Offiah A.C., Poole K., Rajanayagam O., Lyons G., Halsall D., Gurnell M., Chrysis D., Efthymiadou A., Buchanan C., Aylwin S., Chatterjee K.K.
  Lancet Diabetes Endocrinol. 2:619-626(2014) [PubMed] [Europe PMC] [Abstract]

  Cited for: VARIANT CHNG6 VAL-263, CHARACTERIZATION OF VARIANT VAL-263 (ISOFORM ALPHA-1), CHARACTERIZATION OF VARIANT VAL-263 (ISOFORM ALPHA-2).
• Ref.24

  "A novel mutation in THRA gene associated with an atypical phenotype of resistance to thyroid hormone."
  Espiard S., Savagner F., Flamant F., Vlaeminck-Guillem V., Guyot R., Munier M., d'Herbomez M., Bourguet W., Pinto G., Rose C., Rodien P., Wemeau J.L.
  J. Clin. Endocrinol. Metab. 100:2841-2848(2015) [PubMed] [Europe PMC] [Abstract]

  Cited for: VARIANT CHNG6 TYR-359, CHARACTERIZATION OF VARIANT TYR-359 (ISOFORM ALPHA-1), CHARACTERIZATION OF VARIANT TYR-359 (ISOFORM ALPHA-2).
• Ref.25

  "Thyroid hormone resistance syndrome due to mutations in the thyroid hormone receptor alpha gene (THRA)."
  Tylki-Szymanska A., Acuna-Hidalgo R., Krajewska-Walasek M., Lecka-Ambroziak A., Steehouwer M., Gilissen C., Brunner H.G., Jurecka A., Rozdzynska-Swiatkowska A., Hoischen A., Chrzanowska K.H.
  J. Med. Genet. 52:312-316(2015) [PubMed] [Europe PMC] [Abstract]

  Cited for: VARIANTS CHNG6 ARG-398 AND LYS-403 (ISOFORM ALPHA-1).

The disease is caused by mutations affecting the gene represented in this entry.

Disease descriptionA disease characterized by growth retardation, developmental retardation, skeletal dysplasia, borderline low thyroxine levels and high triiodothyronine levels. There is differential sensitivity to thyroid hormone action, with retention of hormone responsiveness in the hypothalamic pituitary axis and liver but skeletal, gastrointestinal, and myocardial resistance.

See also OMIM:614450

Feature key	Position(s)	Length	Description	Graphical view	Feature identifier	Actions
<p>Describes natural variant(s) of the protein sequence.</p><p><a href='../manual/variant' target='_top'>More...</a></p>Natural varianti	263 – 263	1	A → V in CHNG6; no effect on T3 binding; no effect on thyroid hormone-dependent transcriptional activation. 1 Publication <p>Manually curated information for which there is published experimental evidence.</p> <p><a href="/manual/evidences#ECO:0000269">More…</a></p> Manual assertion based on experiment ini Ref.23 "Resistance to thyroid hormone caused by a mutation in thyroid hormone receptor (TR)alpha1 and TRalpha2: clinical, biochemical, and genetic analyses of three related patients." Moran C., Agostini M., Visser W.E., Schoenmakers E., Schoenmakers N., Offiah A.C., Poole K., Rajanayagam O., Lyons G., Halsall D., Gurnell M., Chrysis D., Efthymiadou A., Buchanan C., Aylwin S., Chatterjee K.K. Lancet Diabetes Endocrinol. 2:619-626(2014) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANT CHNG6 VAL-263, CHARACTERIZATION OF VARIANT VAL-263 (ISOFORM ALPHA-1), CHARACTERIZATION OF VARIANT VAL-263 (ISOFORM ALPHA-2).		VAR_074559
<p>Describes natural variant(s) of the protein sequence.</p><p><a href='../manual/variant' target='_top'>More...</a></p>Natural varianti	359 – 359	1	N → Y in CHNG6; atypical phenotype; weak reduction in transcriptional activation. 1 Publication <p>Manually curated information for which there is published experimental evidence.</p> <p><a href="/manual/evidences#ECO:0000269">More…</a></p> Manual assertion based on experiment ini Ref.24 "A novel mutation in THRA gene associated with an atypical phenotype of resistance to thyroid hormone." Espiard S., Savagner F., Flamant F., Vlaeminck-Guillem V., Guyot R., Munier M., d'Herbomez M., Bourguet W., Pinto G., Rose C., Rodien P., Wemeau J.L. J. Clin. Endocrinol. Metab. 100:2841-2848(2015) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANT CHNG6 TYR-359, CHARACTERIZATION OF VARIANT TYR-359 (ISOFORM ALPHA-1), CHARACTERIZATION OF VARIANT TYR-359 (ISOFORM ALPHA-2).		VAR_074560
Isoform Alpha-1 (identifier: P10827-2)
<p>Describes natural variant(s) of the protein sequence.</p><p><a href='../manual/variant' target='_top'>More...</a></p>Natural varianti	263 – 263	1	A → V in CHNG6, reduces T3 binding, impairs thyroid hormone-dependent transcriptional activation, no effect on DNA-binding) (Ref.23. 3 Publications <p>Manually curated information for which there is published experimental evidence.</p> <p><a href="/manual/evidences#ECO:0000269">More…</a></p> Manual assertion based on experiment ini Ref.23 "Resistance to thyroid hormone caused by a mutation in thyroid hormone receptor (TR)alpha1 and TRalpha2: clinical, biochemical, and genetic analyses of three related patients." Moran C., Agostini M., Visser W.E., Schoenmakers E., Schoenmakers N., Offiah A.C., Poole K., Rajanayagam O., Lyons G., Halsall D., Gurnell M., Chrysis D., Efthymiadou A., Buchanan C., Aylwin S., Chatterjee K.K. Lancet Diabetes Endocrinol. 2:619-626(2014) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANT CHNG6 VAL-263, CHARACTERIZATION OF VARIANT VAL-263 (ISOFORM ALPHA-1), CHARACTERIZATION OF VARIANT VAL-263 (ISOFORM ALPHA-2). Ref.24 "A novel mutation in THRA gene associated with an atypical phenotype of resistance to thyroid hormone." Espiard S., Savagner F., Flamant F., Vlaeminck-Guillem V., Guyot R., Munier M., d'Herbomez M., Bourguet W., Pinto G., Rose C., Rodien P., Wemeau J.L. J. Clin. Endocrinol. Metab. 100:2841-2848(2015) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANT CHNG6 TYR-359, CHARACTERIZATION OF VARIANT TYR-359 (ISOFORM ALPHA-1), CHARACTERIZATION OF VARIANT TYR-359 (ISOFORM ALPHA-2). Ref.25 "Thyroid hormone resistance syndrome due to mutations in the thyroid hormone receptor alpha gene (THRA)." Tylki-Szymanska A., Acuna-Hidalgo R., Krajewska-Walasek M., Lecka-Ambroziak A., Steehouwer M., Gilissen C., Brunner H.G., Jurecka A., Rozdzynska-Swiatkowska A., Hoischen A., Chrzanowska K.H. J. Med. Genet. 52:312-316(2015) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CHNG6 ARG-398 AND LYS-403 (ISOFORM ALPHA-1).
<p>Describes natural variant(s) of the protein sequence.</p><p><a href='../manual/variant' target='_top'>More...</a></p>Natural varianti	359 – 359	1	N → Y in CHNG6, decreases transcriptional activity, decreases T3 binding) (Ref.24. 3 Publications <p>Manually curated information for which there is published experimental evidence.</p> <p><a href="/manual/evidences#ECO:0000269">More…</a></p> Manual assertion based on experiment ini Ref.23 "Resistance to thyroid hormone caused by a mutation in thyroid hormone receptor (TR)alpha1 and TRalpha2: clinical, biochemical, and genetic analyses of three related patients." Moran C., Agostini M., Visser W.E., Schoenmakers E., Schoenmakers N., Offiah A.C., Poole K., Rajanayagam O., Lyons G., Halsall D., Gurnell M., Chrysis D., Efthymiadou A., Buchanan C., Aylwin S., Chatterjee K.K. Lancet Diabetes Endocrinol. 2:619-626(2014) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANT CHNG6 VAL-263, CHARACTERIZATION OF VARIANT VAL-263 (ISOFORM ALPHA-1), CHARACTERIZATION OF VARIANT VAL-263 (ISOFORM ALPHA-2). Ref.24 "A novel mutation in THRA gene associated with an atypical phenotype of resistance to thyroid hormone." Espiard S., Savagner F., Flamant F., Vlaeminck-Guillem V., Guyot R., Munier M., d'Herbomez M., Bourguet W., Pinto G., Rose C., Rodien P., Wemeau J.L. J. Clin. Endocrinol. Metab. 100:2841-2848(2015) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANT CHNG6 TYR-359, CHARACTERIZATION OF VARIANT TYR-359 (ISOFORM ALPHA-1), CHARACTERIZATION OF VARIANT TYR-359 (ISOFORM ALPHA-2). Ref.25 "Thyroid hormone resistance syndrome due to mutations in the thyroid hormone receptor alpha gene (THRA)." Tylki-Szymanska A., Acuna-Hidalgo R., Krajewska-Walasek M., Lecka-Ambroziak A., Steehouwer M., Gilissen C., Brunner H.G., Jurecka A., Rozdzynska-Swiatkowska A., Hoischen A., Chrzanowska K.H. J. Med. Genet. 52:312-316(2015) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CHNG6 ARG-398 AND LYS-403 (ISOFORM ALPHA-1).
<p>Describes natural variant(s) of the protein sequence.</p><p><a href='../manual/variant' target='_top'>More...</a></p>Natural varianti	398 – 398	1	P → R in CHNG6) (Ref.25. 3 Publications <p>Manually curated information for which there is published experimental evidence.</p> <p><a href="/manual/evidences#ECO:0000269">More…</a></p> Manual assertion based on experiment ini Ref.23 "Resistance to thyroid hormone caused by a mutation in thyroid hormone receptor (TR)alpha1 and TRalpha2: clinical, biochemical, and genetic analyses of three related patients." Moran C., Agostini M., Visser W.E., Schoenmakers E., Schoenmakers N., Offiah A.C., Poole K., Rajanayagam O., Lyons G., Halsall D., Gurnell M., Chrysis D., Efthymiadou A., Buchanan C., Aylwin S., Chatterjee K.K. Lancet Diabetes Endocrinol. 2:619-626(2014) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANT CHNG6 VAL-263, CHARACTERIZATION OF VARIANT VAL-263 (ISOFORM ALPHA-1), CHARACTERIZATION OF VARIANT VAL-263 (ISOFORM ALPHA-2). Ref.24 "A novel mutation in THRA gene associated with an atypical phenotype of resistance to thyroid hormone." Espiard S., Savagner F., Flamant F., Vlaeminck-Guillem V., Guyot R., Munier M., d'Herbomez M., Bourguet W., Pinto G., Rose C., Rodien P., Wemeau J.L. J. Clin. Endocrinol. Metab. 100:2841-2848(2015) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANT CHNG6 TYR-359, CHARACTERIZATION OF VARIANT TYR-359 (ISOFORM ALPHA-1), CHARACTERIZATION OF VARIANT TYR-359 (ISOFORM ALPHA-2). Ref.25 "Thyroid hormone resistance syndrome due to mutations in the thyroid hormone receptor alpha gene (THRA)." Tylki-Szymanska A., Acuna-Hidalgo R., Krajewska-Walasek M., Lecka-Ambroziak A., Steehouwer M., Gilissen C., Brunner H.G., Jurecka A., Rozdzynska-Swiatkowska A., Hoischen A., Chrzanowska K.H. J. Med. Genet. 52:312-316(2015) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CHNG6 ARG-398 AND LYS-403 (ISOFORM ALPHA-1).
<p>Describes natural variant(s) of the protein sequence.</p><p><a href='../manual/variant' target='_top'>More...</a></p>Natural varianti	403 – 403	1	E → Q in CHNG6) (Ref.25. 3 Publications <p>Manually curated information for which there is published experimental evidence.</p> <p><a href="/manual/evidences#ECO:0000269">More…</a></p> Manual assertion based on experiment ini Ref.23 "Resistance to thyroid hormone caused by a mutation in thyroid hormone receptor (TR)alpha1 and TRalpha2: clinical, biochemical, and genetic analyses of three related patients." Moran C., Agostini M., Visser W.E., Schoenmakers E., Schoenmakers N., Offiah A.C., Poole K., Rajanayagam O., Lyons G., Halsall D., Gurnell M., Chrysis D., Efthymiadou A., Buchanan C., Aylwin S., Chatterjee K.K. Lancet Diabetes Endocrinol. 2:619-626(2014) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANT CHNG6 VAL-263, CHARACTERIZATION OF VARIANT VAL-263 (ISOFORM ALPHA-1), CHARACTERIZATION OF VARIANT VAL-263 (ISOFORM ALPHA-2). Ref.24 "A novel mutation in THRA gene associated with an atypical phenotype of resistance to thyroid hormone." Espiard S., Savagner F., Flamant F., Vlaeminck-Guillem V., Guyot R., Munier M., d'Herbomez M., Bourguet W., Pinto G., Rose C., Rodien P., Wemeau J.L. J. Clin. Endocrinol. Metab. 100:2841-2848(2015) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANT CHNG6 TYR-359, CHARACTERIZATION OF VARIANT TYR-359 (ISOFORM ALPHA-1), CHARACTERIZATION OF VARIANT TYR-359 (ISOFORM ALPHA-2). Ref.25 "Thyroid hormone resistance syndrome due to mutations in the thyroid hormone receptor alpha gene (THRA)." Tylki-Szymanska A., Acuna-Hidalgo R., Krajewska-Walasek M., Lecka-Ambroziak A., Steehouwer M., Gilissen C., Brunner H.G., Jurecka A., Rozdzynska-Swiatkowska A., Hoischen A., Chrzanowska K.H. J. Med. Genet. 52:312-316(2015) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CHNG6 ARG-398 AND LYS-403 (ISOFORM ALPHA-1).

Mutagenesis

Feature key	Position(s)	Length	Description	Graphical view	Feature identifier	Actions
<p>Describes the effect of the experimental mutation of one or more amino acid(s) on the biological properties of the protein.</p><p><a href='../manual/mutagen' target='_top'>More...</a></p>Mutagenesisi	277 – 277	1	S → N: No effect on thyroid hormone binding. 2 Publications <p>Manually curated information for which there is published experimental evidence.</p> <p><a href="/manual/evidences#ECO:0000269">More…</a></p> Manual assertion based on experiment ini Ref.15 "Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor." Borngraeber S., Budny M.J., Chiellini G., Cunha-Lima S.T., Togashi M., Webb P., Baxter J.D., Scanlan T.S., Fletterick R.J. Proc. Natl. Acad. Sci. U.S.A. 100:15358-15363(2003) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION, MUTAGENESIS OF SER-277. Ref.22 "Gaining ligand selectivity in thyroid hormone receptors via entropy." Martinez L., Nascimento A.S., Nunes F.M., Phillips K., Aparicio R., Dias S.M., Figueira A.C., Lin J.H., Nguyen P., Apriletti J.W., Neves F.A., Baxter J.D., Webb P., Skaf M.S., Polikarpov I. Proc. Natl. Acad. Sci. U.S.A. 106:20717-20722(2009) [PubMed] [Europe PMC] [Abstract] Cited for: X-RAY CRYSTALLOGRAPHY (2.01 ANGSTROMS) OF 148-370 IN COMPLEX WITH SYNTHETIC AGONIST, FUNCTION, MUTAGENESIS OF SER-277.

<p>UniProtKB Keywords constitute a <a target="_top" href="/keywords">controlled vocabulary</a> with a hierarchical structure. Keywords summarise the content of a UniProtKB entry and facilitate the search for proteins of interest.<p><a href='/help/keywords' target='_top'>More...</a></p>Keywords - Diseaseⁱ

Organism-specific databases

Chemistry

Polymorphism and mutation databases

<p>Describes post-translational modifications (PTMs) and/or processing events.</p><p><a href='../manual/ptm_processing_section' target='_top'>More...</a></p>PTM / Processingⁱ

Molecule processing

Feature key	Position(s)	Length	Description	Graphical view	Feature identifier	Actions
<p>Describes the extent of a polypeptide chain in the mature protein following processing.</p><p><a href='../manual/chain' target='_top'>More...</a></p>Chaini	1 – 490	490	Thyroid hormone receptor alpha		PRO_0000053424	Add BLAST

Amino acid modifications

Feature key	Position(s)	Length	Description	Graphical view	Feature identifier	Actions
<p>Describes covalent linkages of various types formed between two proteins (interchain cross-links) or between two parts of the same protein (intrachain cross-links), except the disulfide bonds that are annotated in the <a href="/manual/disulfid">‘Disulfide bond’</a> subsection.</p><p><a href='../manual/crosslnk' target='_top'>More...</a></p>Cross-linki	190 – 190		Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)1 Publication <p>Manually curated information for which there is published experimental evidence.</p> <p><a href="/manual/evidences#ECO:0000269">More…</a></p> Manual assertion based on experiment ini Ref.17 "Proteomic analysis of ubiquitinated proteins in normal hepatocyte cell line Chang liver cells." Tan F., Lu L., Cai Y., Wang J., Xie Y., Wang L., Gong Y., Xu B.-E., Wu J., Luo Y., Qiang B., Yuan J., Sun X., Peng X. Proteomics 8:2885-2896(2008) [PubMed] [Europe PMC] [Abstract] Cited for: UBIQUITINATION [LARGE SCALE ANALYSIS] AT LYS-190.

<p>UniProtKB Keywords constitute a <a target="_top" href="/keywords">controlled vocabulary</a> with a hierarchical structure. Keywords summarise the content of a UniProtKB entry and facilitate the search for proteins of interest.<p><a href='/help/keywords' target='_top'>More...</a></p>Keywords - PTMⁱ

Proteomic databases

PTM databases

<p>Provides information on the expression of a gene at the mRNA or protein level in cells or in tissues of multicellular organisms.</p><p><a href='../manual/expression_section' target='_top'>More...</a></p>Expressionⁱ

Gene expression databases

Organism-specific databases

<p>Provides information on the quaternary structure of a protein and on interaction(s) with other proteins or protein complexes.</p><p><a href='../manual/interaction_section' target='_top'>More...</a></p>Interactionⁱ

<p>Provides information about the protein quaternary structure and interaction(s) with other proteins or protein complexes (with the exception of physiological receptor-ligand interactions which are annotated in the <a href="/help/function_section">‘Function’</a> section).</p><p><a href='../manual/subunit_structure' target='_top'>More...</a></p>Subunit structureⁱ

<p>Provides information about binary protein-protein interactions. The data presented in this section are a quality-filtered subset of binary interactions automatically derived from the <a href="http://www.ebi.ac.uk/intact/">IntAct database</a>. It is updated on a monthly basis. Each binary interaction is displayed on a separate line.</p><p><a href='../manual/binary_interactions' target='_top'>More...</a></p>Binary interactionsⁱ

<p>The <a href="http://www.geneontology.org/">Gene Ontology (GO)</a> project provides a set of hierarchical controlled vocabulary split into 3 categories:</p><p><a href='../manual/gene_ontology' target='_top'>More...</a></p>GO - Molecular functionⁱ

• protein domain specific binding Source: UniProtKB

  <p>Inferred from Physical Interaction</p> <p>Covers physical interactions between the gene product of interest and another molecule (or ion, or complex).</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#ipi">GO evidence code guide</a></p> Inferred from physical interactionⁱ

  • 9653119

• TBP-class protein binding Source: UniProtKB

  <p>Inferred from Direct Assay</p> <p>Used to indicate a direct assay for the function, process or component indicated by the GO term.</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#ida">GO evidence code guide</a></p> Inferred from direct assayⁱ

  • 8524305

• transcription factor binding Source: UniProtKB

  <p>Inferred from Physical Interaction</p> <p>Covers physical interactions between the gene product of interest and another molecule (or ion, or complex).</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#ipi">GO evidence code guide</a></p> Inferred from physical interactionⁱ

  • 8524305

Protein-protein interaction databases

Chemistry

<p>Provides information on the tertiary and secondary structure of a protein.</p><p><a href='../manual/structure_section' target='_top'>More...</a></p>Structureⁱ

Secondary structure

Feature key	Position(s)	Length	Description	Graphical view	Feature identifier	Actions
<p>Is used to indicate the positions of experimentally determined helical regions within the protein sequence.</p><p><a href='../manual/helix' target='_top'>More...</a></p>Helixi	148 – 151	4	Combined sources <p>Manually validated information inferred from a combination of experimental and computational evidence.</p> <p><a href="/manual/evidences#ECO:0000244">More…</a></p> Manual assertion inferred from combination of experimental and computational evidencei PDB:3ILZ
<p>Is used to indicate the positions of experimentally determined hydrogen-bonded turns within the protein sequence. These elements correspond to the <span class="caps">DSSP</span> secondary structure code ‘T’.</p><p><a href='../manual/turn' target='_top'>More...</a></p>Turni	152 – 154	3	Combined sources <p>Manually validated information inferred from a combination of experimental and computational evidence.</p> <p><a href="/manual/evidences#ECO:0000244">More…</a></p> Manual assertion inferred from combination of experimental and computational evidencei PDB:3ILZ
<p>Is used to indicate the positions of experimentally determined helical regions within the protein sequence.</p><p><a href='../manual/helix' target='_top'>More...</a></p>Helixi	162 – 176	15	Combined sources <p>Manually validated information inferred from a combination of experimental and computational evidence.</p> <p><a href="/manual/evidences#ECO:0000244">More…</a></p> Manual assertion inferred from combination of experimental and computational evidencei PDB:3ILZ
<p>Is used to indicate the positions of experimentally determined hydrogen-bonded turns within the protein sequence. These elements correspond to the <span class="caps">DSSP</span> secondary structure code ‘T’.</p><p><a href='../manual/turn' target='_top'>More...</a></p>Turni	180 – 184	5	Combined sources <p>Manually validated information inferred from a combination of experimental and computational evidence.</p> <p><a href="/manual/evidences#ECO:0000244">More…</a></p> Manual assertion inferred from combination of experimental and computational evidencei PDB:2H79
<p>Is used to indicate the positions of experimentally determined hydrogen-bonded turns within the protein sequence. These elements correspond to the <span class="caps">DSSP</span> secondary structure code ‘T’.</p><p><a href='../manual/turn' target='_top'>More...</a></p>Turni	186 – 188	3	Combined sources <p>Manually validated information inferred from a combination of experimental and computational evidence.</p> <p><a href="/manual/evidences#ECO:0000244">More…</a></p> Manual assertion inferred from combination of experimental and computational evidencei PDB:3ILZ
<p>Is used to indicate the positions of experimentally determined beta strands within the protein sequence.</p><p><a href='../manual/strand' target='_top'>More...</a></p>Beta strandi	189 – 191	3	Combined sources <p>Manually validated information inferred from a combination of experimental and computational evidence.</p> <p><a href="/manual/evidences#ECO:0000244">More…</a></p> Manual assertion inferred from combination of experimental and computational evidencei PDB:3ILZ
<p>Is used to indicate the positions of experimentally determined beta strands within the protein sequence.</p><p><a href='../manual/strand' target='_top'>More...</a></p>Beta strandi	196 – 198	3	Combined sources <p>Manually validated information inferred from a combination of experimental and computational evidence.</p> <p><a href="/manual/evidences#ECO:0000244">More…</a></p> Manual assertion inferred from combination of experimental and computational evidencei PDB:2H79
<p>Is used to indicate the positions of experimentally determined helical regions within the protein sequence.</p><p><a href='../manual/helix' target='_top'>More...</a></p>Helixi	212 – 234	23	Combined sources <p>Manually validated information inferred from a combination of experimental and computational evidence.</p> <p><a href="/manual/evidences#ECO:0000244">More…</a></p> Manual assertion inferred from combination of experimental and computational evidencei PDB:3ILZ
<p>Is used to indicate the positions of experimentally determined helical regions within the protein sequence.</p><p><a href='../manual/helix' target='_top'>More...</a></p>Helixi	237 – 240	4	Combined sources <p>Manually validated information inferred from a combination of experimental and computational evidence.</p> <p><a href="/manual/evidences#ECO:0000244">More…</a></p> Manual assertion inferred from combination of experimental and computational evidencei PDB:3ILZ
<p>Is used to indicate the positions of experimentally determined helical regions within the protein sequence.</p><p><a href='../manual/helix' target='_top'>More...</a></p>Helixi	244 – 264	21	Combined sources <p>Manually validated information inferred from a combination of experimental and computational evidence.</p> <p><a href="/manual/evidences#ECO:0000244">More…</a></p> Manual assertion inferred from combination of experimental and computational evidencei PDB:3ILZ
<p>Is used to indicate the positions of experimentally determined hydrogen-bonded turns within the protein sequence. These elements correspond to the <span class="caps">DSSP</span> secondary structure code ‘T’.</p><p><a href='../manual/turn' target='_top'>More...</a></p>Turni	269 – 272	4	Combined sources <p>Manually validated information inferred from a combination of experimental and computational evidence.</p> <p><a href="/manual/evidences#ECO:0000244">More…</a></p> Manual assertion inferred from combination of experimental and computational evidencei PDB:3ILZ
<p>Is used to indicate the positions of experimentally determined beta strands within the protein sequence.</p><p><a href='../manual/strand' target='_top'>More...</a></p>Beta strandi	273 – 276	4	Combined sources <p>Manually validated information inferred from a combination of experimental and computational evidence.</p> <p><a href="/manual/evidences#ECO:0000244">More…</a></p> Manual assertion inferred from combination of experimental and computational evidencei PDB:3ILZ
<p>Is used to indicate the positions of experimentally determined hydrogen-bonded turns within the protein sequence. These elements correspond to the <span class="caps">DSSP</span> secondary structure code ‘T’.</p><p><a href='../manual/turn' target='_top'>More...</a></p>Turni	277 – 279	3	Combined sources <p>Manually validated information inferred from a combination of experimental and computational evidence.</p> <p><a href="/manual/evidences#ECO:0000244">More…</a></p> Manual assertion inferred from combination of experimental and computational evidencei PDB:3ILZ
<p>Is used to indicate the positions of experimentally determined beta strands within the protein sequence.</p><p><a href='../manual/strand' target='_top'>More...</a></p>Beta strandi	280 – 282	3	Combined sources <p>Manually validated information inferred from a combination of experimental and computational evidence.</p> <p><a href="/manual/evidences#ECO:0000244">More…</a></p> Manual assertion inferred from combination of experimental and computational evidencei PDB:3ILZ
<p>Is used to indicate the positions of experimentally determined helical regions within the protein sequence.</p><p><a href='../manual/helix' target='_top'>More...</a></p>Helixi	284 – 289	6	Combined sources <p>Manually validated information inferred from a combination of experimental and computational evidence.</p> <p><a href="/manual/evidences#ECO:0000244">More…</a></p> Manual assertion inferred from combination of experimental and computational evidencei PDB:3ILZ
<p>Is used to indicate the positions of experimentally determined hydrogen-bonded turns within the protein sequence. These elements correspond to the <span class="caps">DSSP</span> secondary structure code ‘T’.</p><p><a href='../manual/turn' target='_top'>More...</a></p>Turni	290 – 293	4	Combined sources <p>Manually validated information inferred from a combination of experimental and computational evidence.</p> <p><a href="/manual/evidences#ECO:0000244">More…</a></p> Manual assertion inferred from combination of experimental and computational evidencei PDB:3ILZ
<p>Is used to indicate the positions of experimentally determined helical regions within the protein sequence.</p><p><a href='../manual/helix' target='_top'>More...</a></p>Helixi	294 – 306	13	Combined sources <p>Manually validated information inferred from a combination of experimental and computational evidence.</p> <p><a href="/manual/evidences#ECO:0000244">More…</a></p> Manual assertion inferred from combination of experimental and computational evidencei PDB:3ILZ
<p>Is used to indicate the positions of experimentally determined helical regions within the protein sequence.</p><p><a href='../manual/helix' target='_top'>More...</a></p>Helixi	307 – 309	3	Combined sources <p>Manually validated information inferred from a combination of experimental and computational evidence.</p> <p><a href="/manual/evidences#ECO:0000244">More…</a></p> Manual assertion inferred from combination of experimental and computational evidencei PDB:3ILZ
<p>Is used to indicate the positions of experimentally determined helical regions within the protein sequence.</p><p><a href='../manual/helix' target='_top'>More...</a></p>Helixi	313 – 324	12	Combined sources <p>Manually validated information inferred from a combination of experimental and computational evidence.</p> <p><a href="/manual/evidences#ECO:0000244">More…</a></p> Manual assertion inferred from combination of experimental and computational evidencei PDB:3ILZ
<p>Is used to indicate the positions of experimentally determined beta strands within the protein sequence.</p><p><a href='../manual/strand' target='_top'>More...</a></p>Beta strandi	329 – 331	3	Combined sources <p>Manually validated information inferred from a combination of experimental and computational evidence.</p> <p><a href="/manual/evidences#ECO:0000244">More…</a></p> Manual assertion inferred from combination of experimental and computational evidencei PDB:3ILZ
<p>Is used to indicate the positions of experimentally determined helical regions within the protein sequence.</p><p><a href='../manual/helix' target='_top'>More...</a></p>Helixi	335 – 356	22	Combined sources <p>Manually validated information inferred from a combination of experimental and computational evidence.</p> <p><a href="/manual/evidences#ECO:0000244">More…</a></p> Manual assertion inferred from combination of experimental and computational evidencei PDB:3ILZ
<p>Is used to indicate the positions of experimentally determined helical regions within the protein sequence.</p><p><a href='../manual/helix' target='_top'>More...</a></p>Helixi	363 – 370	8	Combined sources <p>Manually validated information inferred from a combination of experimental and computational evidence.</p> <p><a href="/manual/evidences#ECO:0000244">More…</a></p> Manual assertion inferred from combination of experimental and computational evidencei PDB:3ILZ

3D structure databases

Miscellaneous databases

<p>Provides information on sequence similarities with other proteins and the domain(s) present in a protein.</p><p><a href='../manual/family_and_domains_section' target='_top'>More...</a></p>Family & Domainsⁱ

Region

Feature key	Position(s)	Length	Description	Graphical view	Feature identifier	Actions
<p>Describes a region of interest that cannot be described in other subsections.</p><p><a href='../manual/region' target='_top'>More...</a></p>Regioni	1 – 52	52	Modulating			Add BLAST
<p>Describes a region of interest that cannot be described in other subsections.</p><p><a href='../manual/region' target='_top'>More...</a></p>Regioni	190 – 370	181	Ligand-binding			Add BLAST

<p>Provides general information on the biological role of a domain. The term ‘domain’ is intended here in its wide acceptation, it may be a structural domain, a transmembrane region or a functional domain. Several domains are described in this subsection.</p><p><a href='../manual/domain_cc' target='_top'>More...</a></p>Domainⁱ

<p>Provides information about the sequence similarity with other proteins.</p><p><a href='../manual/sequence_similarities' target='_top'>More...</a></p>Sequence similaritiesⁱ

Zinc finger

Feature key	Position(s)	Length	Description	Graphical view	Feature identifier	Actions
<p>Specifies the position(s) and type(s) of zinc fingers within the protein.</p><p><a href='../manual/zn_fing' target='_top'>More...</a></p>Zinc fingeri	53 – 73	21	NR C4-typePROSITE-ProRule annotation <p>Manual validated information which has been generated by the UniProtKB automatic annotation system.</p> <p><a href="/manual/evidences#ECO:0000255">More…</a></p> Manual assertion according to rulesi PROSITE-ProRule:PRU00407			Add BLAST
<p>Specifies the position(s) and type(s) of zinc fingers within the protein.</p><p><a href='../manual/zn_fing' target='_top'>More...</a></p>Zinc fingeri	91 – 115	25	NR C4-typePROSITE-ProRule annotation <p>Manual validated information which has been generated by the UniProtKB automatic annotation system.</p> <p><a href="/manual/evidences#ECO:0000255">More…</a></p> Manual assertion according to rulesi PROSITE-ProRule:PRU00407			Add BLAST

<p>UniProtKB Keywords constitute a <a target="_top" href="/keywords">controlled vocabulary</a> with a hierarchical structure. Keywords summarise the content of a UniProtKB entry and facilitate the search for proteins of interest.<p><a href='/help/keywords' target='_top'>More...</a></p>Keywords - Domainⁱ

Phylogenomic databases

Family and domain databases

<p>Displays by default the canonical protein sequence and upon request all isoforms described in the entry. It also includes information pertinent to the sequence(s), including length and molecular weight.</p><p><a href='../manual/sequences_section' target='_top'>More...</a></p>Sequences (4)ⁱ

<p>Indicates if the <a href="/help/canonical_and_isoforms">canonical sequence</a> displayed by default in the entry is complete or not.</p><p><a href='../manual/sequence_status' target='_top'>More...</a></p>Sequence statusⁱ: Complete.

This entry describes 4<p>Lists the alternative protein sequences (isoforms) that can be generated from the same gene by a single or by the combination of up to four biological events (alternative promoter usage, alternative splicing, alternative initiation and ribosomal frameshifting). Additionally, this section gives relevant information on each alternative protein isoform.</p><p><a href='../manual/alternative_products' target='_top'>More...</a></p> isoformsⁱ produced by alternative splicing. AlignAdd to basketAdded to basket

        10         20         30         40         50
MEQKPSKVEC GSDPEENSAR SPDGKRKRKN GQCSLKTSMS GYIPSYLDKD 
        60         70         80         90        100
EQCVVCGDKA TGYHYRCITC EGCKGFFRRT IQKNLHPTYS CKYDSCCVID 
       110        120        130        140        150
KITRNQCQLC RFKKCIAVGM AMDLVLDDSK RVAKRKLIEQ NRERRRKEEM 
       160        170        180        190        200
IRSLQQRPEP TPEEWDLIHI ATEAHRSTNA QGSHWKQRRK FLPDDIGQSP 
       210        220        230        240        250
IVSMPDGDKV DLEAFSEFTK IITPAITRVV DFAKKLPMFS ELPCEDQIIL 
       260        270        280        290        300
LKGCCMEIMS LRAAVRYDPE SDTLTLSGEM AVKREQLKNG GLGVVSDAIF 
       310        320        330        340        350
ELGKSLSAFN LDDTEVALLQ AVLLMSTDRS GLLCVDKIEK SQEAYLLAFE 
       360        370        380        390        400
HYVNHRKHNI PHFWPKLLMK EREVQSSILY KGAAAEGRPG GSLGVHPEGQ 
       410        420        430        440        450
QLLGMHVVQG PQVRQLEQQL GEAGSLQGPV LQHQSPKSPQ QRLLELLHRS 
       460        470        480        490
GILHARAVCG EDDSSEADSP SSSEEEPEVC EDLAGNAASP            

        10         20         30         40         50
MEQKPSKVEC GSDPEENSAR SPDGKRKRKN GQCSLKTSMS GYIPSYLDKD 
        60         70         80         90        100
EQCVVCGDKA TGYHYRCITC EGCKGFFRRT IQKNLHPTYS CKYDSCCVID 
       110        120        130        140        150
KITRNQCQLC RFKKCIAVGM AMDLVLDDSK RVAKRKLIEQ NRERRRKEEM 
       160        170        180        190        200
IRSLQQRPEP TPEEWDLIHI ATEAHRSTNA QGSHWKQRRK FLPDDIGQSP 
       210        220        230        240        250
IVSMPDGDKV DLEAFSEFTK IITPAITRVV DFAKKLPMFS ELPCEDQIIL 
       260        270        280        290        300
LKGCCMEIMS LRAAVRYDPE SDTLTLSGEM AVKREQLKNG GLGVVSDAIF 
       310        320        330        340        350
ELGKSLSAFN LDDTEVALLQ AVLLMSTDRS GLLCVDKIEK SQEAYLLAFE 
       360        370        380        390        400
HYVNHRKHNI PHFWPKLLMK VTDLRMIGAC HASRFLHMKV ECPTELFPPL 
       410
FLEVFEDQEV                                             

        10         20         30         40         50
MEQKPSKVEC GSDPEENSAR SPDGKRKRKN GQCSLKTSMS GYIPSYLDKD 
        60         70         80         90        100
EQCVVCGDKA TGYHYRCITC EGCKGFFRRT IQKNLHPTYS CKYDSCCVID 
       110        120        130        140        150
KITRNQCQLC RFKKCIAVGM AMDLVLDDSK RVAKRKLIEQ NRERRRKEEM 
       160        170        180        190        200
IRSLQQRPEP TPEEWDLIHI ATEAHRSTNA QGSHWKQRRK FLPDDIGQSP 
       210        220        230        240        250
IVSMPDGDKV DLEAFSEFTK IITPAITRVV DFAKKLPMFS ELPCEDQIIL 
       260        270        280        290        300
LKGCCMEIMS LRAAVRYDPE SDTLTLSGEM AVKREQLKNG GLGVVSDAIF 
       310        320        330        340        350
ELGKSLSAFN LDDTEVALLQ AVLLMSTDRS GLLCVDKIEK SQEAYLLAFE 
       360        370        380        390        400
HYVNHRKHNI PHFWPKLLMK GPQVRQLEQQ LGEAGSLQGP VLQHQSPKSP 
       410        420        430        440        450
QQRLLELLHR SGILHARAVC GEDDSSEADS PSSSEEEPEV CEDLAGNAAS 

P                                             

        10         20         30         40         50
MEQKPSKVEC GSDPEENSAR SPDGKRKRKN GQCSLKTSMS GYIPSYLDKD 
        60         70         80         90        100
EQCVVCGDKA TGYHYRCITC EGCKGFFRRT IQKNLHPTYS CKYDSCCVID 
       110        120        130        140        150
KITRNQCQLC RFKKCIAVGM AMDLVLDDSK RVAKRKLIEQ NRERRRKEEM 
       160        170        180        190        200
IRSLQQRPEP TPEEWDLIHI ATEAHRSTNA QGSHWKQRRK FLPDDIGQSP 
       210        220        230        240        250
IVSMPDGDKV DLEAFSEFTK IITPAITRVV DFAKKLPMFS ELPCEDQIIL 
       260        270        280        290        300
LKGCCMEIMS LRAAVRYDPE SDTLTLSGEM AVKREQLKNG GLGVVSDAIF 
       310        320        330        340        350
ELGKSLSAFN LDDTEVALLQ AVLLMSTDRS GLLCVDKIEK SQEAYLLAFE 
       360        370        380        390        400
HYVNHRKHNI PHFWPKLLMK VRQLEQQLGE AGSLQGPVLQ HQSPKSPQQR 
       410        420        430        440 
LLELLHRSGI LHARAVCGED DSSEADSPSS SEEEPEVCED LAGNAASP 

Experimental Info

Feature key	Position(s)	Length	Description	Graphical view	Feature identifier	Actions
<p>Reports difference(s) between the canonical sequence (displayed by default in the entry) and the different sequence submissions merged in the entry. These various submissions may originate from different sequencing projects, different types of experiments, or different biological samples. Sequence conflicts are usually of unknown origin.</p><p><a href='../manual/conflict' target='_top'>More...</a></p>Sequence conflicti	37 – 37	1	T → S in CAA68539 (PubMed:3684612).Curated
<p>Reports difference(s) between the canonical sequence (displayed by default in the entry) and the different sequence submissions merged in the entry. These various submissions may originate from different sequencing projects, different types of experiments, or different biological samples. Sequence conflicts are usually of unknown origin.</p><p><a href='../manual/conflict' target='_top'>More...</a></p>Sequence conflicti	119 – 119	1	G → A in CAA68539 (PubMed:3684612).Curated
<p>Reports difference(s) between the canonical sequence (displayed by default in the entry) and the different sequence submissions merged in the entry. These various submissions may originate from different sequencing projects, different types of experiments, or different biological samples. Sequence conflicts are usually of unknown origin.</p><p><a href='../manual/conflict' target='_top'>More...</a></p>Sequence conflicti	285 – 285	1	E → A in CAB57886 (PubMed:1850510).Curated
<p>Reports difference(s) between the canonical sequence (displayed by default in the entry) and the different sequence submissions merged in the entry. These various submissions may originate from different sequencing projects, different types of experiments, or different biological samples. Sequence conflicts are usually of unknown origin.</p><p><a href='../manual/conflict' target='_top'>More...</a></p>Sequence conflicti	285 – 285	1	E → A in CAA38899 (PubMed:1850510).Curated

Natural variant

Feature key	Position(s)	Length	Description	Graphical view	Feature identifier	Actions
<p>Describes natural variant(s) of the protein sequence.</p><p><a href='../manual/variant' target='_top'>More...</a></p>Natural varianti	263 – 263	1	A → V in CHNG6; no effect on T3 binding; no effect on thyroid hormone-dependent transcriptional activation. 1 Publication <p>Manually curated information for which there is published experimental evidence.</p> <p><a href="/manual/evidences#ECO:0000269">More…</a></p> Manual assertion based on experiment ini Ref.23 "Resistance to thyroid hormone caused by a mutation in thyroid hormone receptor (TR)alpha1 and TRalpha2: clinical, biochemical, and genetic analyses of three related patients." Moran C., Agostini M., Visser W.E., Schoenmakers E., Schoenmakers N., Offiah A.C., Poole K., Rajanayagam O., Lyons G., Halsall D., Gurnell M., Chrysis D., Efthymiadou A., Buchanan C., Aylwin S., Chatterjee K.K. Lancet Diabetes Endocrinol. 2:619-626(2014) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANT CHNG6 VAL-263, CHARACTERIZATION OF VARIANT VAL-263 (ISOFORM ALPHA-1), CHARACTERIZATION OF VARIANT VAL-263 (ISOFORM ALPHA-2).		VAR_074559
<p>Describes natural variant(s) of the protein sequence.</p><p><a href='../manual/variant' target='_top'>More...</a></p>Natural varianti	359 – 359	1	N → Y in CHNG6; atypical phenotype; weak reduction in transcriptional activation. 1 Publication <p>Manually curated information for which there is published experimental evidence.</p> <p><a href="/manual/evidences#ECO:0000269">More…</a></p> Manual assertion based on experiment ini Ref.24 "A novel mutation in THRA gene associated with an atypical phenotype of resistance to thyroid hormone." Espiard S., Savagner F., Flamant F., Vlaeminck-Guillem V., Guyot R., Munier M., d'Herbomez M., Bourguet W., Pinto G., Rose C., Rodien P., Wemeau J.L. J. Clin. Endocrinol. Metab. 100:2841-2848(2015) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANT CHNG6 TYR-359, CHARACTERIZATION OF VARIANT TYR-359 (ISOFORM ALPHA-1), CHARACTERIZATION OF VARIANT TYR-359 (ISOFORM ALPHA-2).		VAR_074560
Isoform Alpha-1 (identifier: P10827-2)
<p>Describes natural variant(s) of the protein sequence.</p><p><a href='../manual/variant' target='_top'>More...</a></p>Natural varianti	263 – 263	1	A → V in CHNG6, reduces T3 binding, impairs thyroid hormone-dependent transcriptional activation, no effect on DNA-binding) (Ref.23. 3 Publications <p>Manually curated information for which there is published experimental evidence.</p> <p><a href="/manual/evidences#ECO:0000269">More…</a></p> Manual assertion based on experiment ini Ref.23 "Resistance to thyroid hormone caused by a mutation in thyroid hormone receptor (TR)alpha1 and TRalpha2: clinical, biochemical, and genetic analyses of three related patients." Moran C., Agostini M., Visser W.E., Schoenmakers E., Schoenmakers N., Offiah A.C., Poole K., Rajanayagam O., Lyons G., Halsall D., Gurnell M., Chrysis D., Efthymiadou A., Buchanan C., Aylwin S., Chatterjee K.K. Lancet Diabetes Endocrinol. 2:619-626(2014) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANT CHNG6 VAL-263, CHARACTERIZATION OF VARIANT VAL-263 (ISOFORM ALPHA-1), CHARACTERIZATION OF VARIANT VAL-263 (ISOFORM ALPHA-2). Ref.24 "A novel mutation in THRA gene associated with an atypical phenotype of resistance to thyroid hormone." Espiard S., Savagner F., Flamant F., Vlaeminck-Guillem V., Guyot R., Munier M., d'Herbomez M., Bourguet W., Pinto G., Rose C., Rodien P., Wemeau J.L. J. Clin. Endocrinol. Metab. 100:2841-2848(2015) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANT CHNG6 TYR-359, CHARACTERIZATION OF VARIANT TYR-359 (ISOFORM ALPHA-1), CHARACTERIZATION OF VARIANT TYR-359 (ISOFORM ALPHA-2). Ref.25 "Thyroid hormone resistance syndrome due to mutations in the thyroid hormone receptor alpha gene (THRA)." Tylki-Szymanska A., Acuna-Hidalgo R., Krajewska-Walasek M., Lecka-Ambroziak A., Steehouwer M., Gilissen C., Brunner H.G., Jurecka A., Rozdzynska-Swiatkowska A., Hoischen A., Chrzanowska K.H. J. Med. Genet. 52:312-316(2015) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CHNG6 ARG-398 AND LYS-403 (ISOFORM ALPHA-1).
<p>Describes natural variant(s) of the protein sequence.</p><p><a href='../manual/variant' target='_top'>More...</a></p>Natural varianti	359 – 359	1	N → Y in CHNG6, decreases transcriptional activity, decreases T3 binding) (Ref.24. 3 Publications <p>Manually curated information for which there is published experimental evidence.</p> <p><a href="/manual/evidences#ECO:0000269">More…</a></p> Manual assertion based on experiment ini Ref.23 "Resistance to thyroid hormone caused by a mutation in thyroid hormone receptor (TR)alpha1 and TRalpha2: clinical, biochemical, and genetic analyses of three related patients." Moran C., Agostini M., Visser W.E., Schoenmakers E., Schoenmakers N., Offiah A.C., Poole K., Rajanayagam O., Lyons G., Halsall D., Gurnell M., Chrysis D., Efthymiadou A., Buchanan C., Aylwin S., Chatterjee K.K. Lancet Diabetes Endocrinol. 2:619-626(2014) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANT CHNG6 VAL-263, CHARACTERIZATION OF VARIANT VAL-263 (ISOFORM ALPHA-1), CHARACTERIZATION OF VARIANT VAL-263 (ISOFORM ALPHA-2). Ref.24 "A novel mutation in THRA gene associated with an atypical phenotype of resistance to thyroid hormone." Espiard S., Savagner F., Flamant F., Vlaeminck-Guillem V., Guyot R., Munier M., d'Herbomez M., Bourguet W., Pinto G., Rose C., Rodien P., Wemeau J.L. J. Clin. Endocrinol. Metab. 100:2841-2848(2015) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANT CHNG6 TYR-359, CHARACTERIZATION OF VARIANT TYR-359 (ISOFORM ALPHA-1), CHARACTERIZATION OF VARIANT TYR-359 (ISOFORM ALPHA-2). Ref.25 "Thyroid hormone resistance syndrome due to mutations in the thyroid hormone receptor alpha gene (THRA)." Tylki-Szymanska A., Acuna-Hidalgo R., Krajewska-Walasek M., Lecka-Ambroziak A., Steehouwer M., Gilissen C., Brunner H.G., Jurecka A., Rozdzynska-Swiatkowska A., Hoischen A., Chrzanowska K.H. J. Med. Genet. 52:312-316(2015) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CHNG6 ARG-398 AND LYS-403 (ISOFORM ALPHA-1).
<p>Describes natural variant(s) of the protein sequence.</p><p><a href='../manual/variant' target='_top'>More...</a></p>Natural varianti	398 – 398	1	P → R in CHNG6) (Ref.25. 3 Publications <p>Manually curated information for which there is published experimental evidence.</p> <p><a href="/manual/evidences#ECO:0000269">More…</a></p> Manual assertion based on experiment ini Ref.23 "Resistance to thyroid hormone caused by a mutation in thyroid hormone receptor (TR)alpha1 and TRalpha2: clinical, biochemical, and genetic analyses of three related patients." Moran C., Agostini M., Visser W.E., Schoenmakers E., Schoenmakers N., Offiah A.C., Poole K., Rajanayagam O., Lyons G., Halsall D., Gurnell M., Chrysis D., Efthymiadou A., Buchanan C., Aylwin S., Chatterjee K.K. Lancet Diabetes Endocrinol. 2:619-626(2014) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANT CHNG6 VAL-263, CHARACTERIZATION OF VARIANT VAL-263 (ISOFORM ALPHA-1), CHARACTERIZATION OF VARIANT VAL-263 (ISOFORM ALPHA-2). Ref.24 "A novel mutation in THRA gene associated with an atypical phenotype of resistance to thyroid hormone." Espiard S., Savagner F., Flamant F., Vlaeminck-Guillem V., Guyot R., Munier M., d'Herbomez M., Bourguet W., Pinto G., Rose C., Rodien P., Wemeau J.L. J. Clin. Endocrinol. Metab. 100:2841-2848(2015) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANT CHNG6 TYR-359, CHARACTERIZATION OF VARIANT TYR-359 (ISOFORM ALPHA-1), CHARACTERIZATION OF VARIANT TYR-359 (ISOFORM ALPHA-2). Ref.25 "Thyroid hormone resistance syndrome due to mutations in the thyroid hormone receptor alpha gene (THRA)." Tylki-Szymanska A., Acuna-Hidalgo R., Krajewska-Walasek M., Lecka-Ambroziak A., Steehouwer M., Gilissen C., Brunner H.G., Jurecka A., Rozdzynska-Swiatkowska A., Hoischen A., Chrzanowska K.H. J. Med. Genet. 52:312-316(2015) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CHNG6 ARG-398 AND LYS-403 (ISOFORM ALPHA-1).
<p>Describes natural variant(s) of the protein sequence.</p><p><a href='../manual/variant' target='_top'>More...</a></p>Natural varianti	403 – 403	1	E → Q in CHNG6) (Ref.25. 3 Publications <p>Manually curated information for which there is published experimental evidence.</p> <p><a href="/manual/evidences#ECO:0000269">More…</a></p> Manual assertion based on experiment ini Ref.23 "Resistance to thyroid hormone caused by a mutation in thyroid hormone receptor (TR)alpha1 and TRalpha2: clinical, biochemical, and genetic analyses of three related patients." Moran C., Agostini M., Visser W.E., Schoenmakers E., Schoenmakers N., Offiah A.C., Poole K., Rajanayagam O., Lyons G., Halsall D., Gurnell M., Chrysis D., Efthymiadou A., Buchanan C., Aylwin S., Chatterjee K.K. Lancet Diabetes Endocrinol. 2:619-626(2014) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANT CHNG6 VAL-263, CHARACTERIZATION OF VARIANT VAL-263 (ISOFORM ALPHA-1), CHARACTERIZATION OF VARIANT VAL-263 (ISOFORM ALPHA-2). Ref.24 "A novel mutation in THRA gene associated with an atypical phenotype of resistance to thyroid hormone." Espiard S., Savagner F., Flamant F., Vlaeminck-Guillem V., Guyot R., Munier M., d'Herbomez M., Bourguet W., Pinto G., Rose C., Rodien P., Wemeau J.L. J. Clin. Endocrinol. Metab. 100:2841-2848(2015) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANT CHNG6 TYR-359, CHARACTERIZATION OF VARIANT TYR-359 (ISOFORM ALPHA-1), CHARACTERIZATION OF VARIANT TYR-359 (ISOFORM ALPHA-2). Ref.25 "Thyroid hormone resistance syndrome due to mutations in the thyroid hormone receptor alpha gene (THRA)." Tylki-Szymanska A., Acuna-Hidalgo R., Krajewska-Walasek M., Lecka-Ambroziak A., Steehouwer M., Gilissen C., Brunner H.G., Jurecka A., Rozdzynska-Swiatkowska A., Hoischen A., Chrzanowska K.H. J. Med. Genet. 52:312-316(2015) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CHNG6 ARG-398 AND LYS-403 (ISOFORM ALPHA-1).

Alternative sequence

Feature key	Position(s)	Length	Description	Graphical view	Feature identifier	Actions
<p>Describes the sequence of naturally occurring alternative protein isoform(s). The changes in the amino acid sequence may be due to alternative splicing, alternative promoter usage, alternative initiation, or ribosomal frameshifting. The information stored in this subsection is used to automatically construct alternative protein sequence(s) for display.</p><p><a href='../manual/var_seq' target='_top'>More...</a></p>Alternative sequencei	371 – 490	120	EREVQ…NAASP → VTDLRMIGACHASRFLHMKV ECPTELFPPLFLEVFEDQEV in isoform Alpha-1. 2 Publications <p>Manually curated information that is based on statements in scientific articles for which there is no experimental support.</p> <p><a href="/manual/evidences#ECO:0000303">More…</a></p> Manual assertion based on opinion ini Ref.1 "Genomic organization of the human thyroid hormone receptor alpha (c-erbA-1) gene." Laudet V., Begue A., Henry C., Joubel A., Martin P., Stehelin D., Saule S. Nucleic Acids Res. 19:1105-1112(1991) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS ALPHA-1 AND ALPHA-2). Ref.2 "Two erbA homologs encoding proteins with different T3 binding capacities are transcribed from opposite DNA strands of the same genetic locus." Miyajima N., Horiuchi R., Shibuya Y., Fukushige S., Matsubara K., Toyoshima K., Yamamoto T. Cell 57:31-39(1989) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA-1 AND ALPHA-2).		VSP_003621	Add BLAST
<p>Describes the sequence of naturally occurring alternative protein isoform(s). The changes in the amino acid sequence may be due to alternative splicing, alternative promoter usage, alternative initiation, or ribosomal frameshifting. The information stored in this subsection is used to automatically construct alternative protein sequence(s) for display.</p><p><a href='../manual/var_seq' target='_top'>More...</a></p>Alternative sequencei	371 – 412	42	Missing in isoform Alpha-4. 1 Publication <p>Manually curated information that is based on statements in scientific articles for which there is no experimental support.</p> <p><a href="/manual/evidences#ECO:0000303">More…</a></p> Manual assertion based on opinion ini Ref.10 Liu C., Li L., Liu B., Zang X. Submitted (JUN-2002) to the EMBL/GenBank/DDBJ databases Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 280-451 (ISOFORM ALPHA-4).		VSP_003623	Add BLAST
<p>Describes the sequence of naturally occurring alternative protein isoform(s). The changes in the amino acid sequence may be due to alternative splicing, alternative promoter usage, alternative initiation, or ribosomal frameshifting. The information stored in this subsection is used to automatically construct alternative protein sequence(s) for display.</p><p><a href='../manual/var_seq' target='_top'>More...</a></p>Alternative sequencei	371 – 409	39	Missing in isoform Alpha-3. 1 Publication <p>Manually curated information that is based on statements in scientific articles for which there is no experimental support.</p> <p><a href="/manual/evidences#ECO:0000303">More…</a></p> Manual assertion based on opinion ini Ref.8 "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)." The MGC Project Team Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS ALPHA-2 AND ALPHA-3).		VSP_003622	Add BLAST

Sequence databases

Genome annotation databases

<p>UniProtKB Keywords constitute a <a target="_top" href="/keywords">controlled vocabulary</a> with a hierarchical structure. Keywords summarise the content of a UniProtKB entry and facilitate the search for proteins of interest.<p><a href='/help/keywords' target='_top'>More...</a></p>Keywords - Coding sequence diversityⁱ

<p>Is used to point to information related to entries and found in data collections other than UniProtKB.</p><p><a href='../manual/cross_references_section' target='_top'>More...</a></p>Cross-referencesⁱ

Sequence databases

3D structure databases

Protein-protein interaction databases

Chemistry

PTM databases

Polymorphism and mutation databases

Proteomic databases

Protocols and materials databases

Genome annotation databases

Organism-specific databases

Phylogenomic databases

Enzyme and pathway databases

Miscellaneous databases

Gene expression databases

Family and domain databases

<p>Provides general information on the entry.</p><p><a href='../manual/entry_information_section' target='_top'>More...</a></p>Entry informationⁱ

<p>Contains any relevant information that doesn’t fit in any other defined sections</p><p><a href='../manual/miscellaneous_section' target='_top'>More...</a></p>Miscellaneousⁱ

<p>UniProtKB Keywords constitute a <a target="_top" href="/keywords">controlled vocabulary</a> with a hierarchical structure. Keywords summarise the content of a UniProtKB entry and facilitate the search for proteins of interest.<p><a href='/help/keywords' target='_top'>More...</a></p>Keywords - Technical termⁱ

Documents

1. Human chromosome 17
   Human chromosome 17: entries, gene names and cross-references to MIM
2. Human entries with polymorphisms or disease mutations
   List of human entries with polymorphisms or disease mutations
3. Human polymorphisms and disease mutations
   Index of human polymorphisms and disease mutations
4. MIM cross-references
   Online Mendelian Inheritance in Man (MIM) cross-references in UniProtKB/Swiss-Prot
5. PDB cross-references
   Index of Protein Data Bank (PDB) cross-references
6. SIMILARITY comments
   Index of protein domains and families

<p>Provides links to the UniProt Reference Clusters (<a href="/help/uniref">UniRef</a>). UniRef consists of clusters for UniProtKB sequences (including isoforms) and selected UniParc sequences, in order to obtain complete coverage of the sequence space at resolutions of 100%, 90% and 50% identity.</p><p><a href='../manual/similar_proteins_section' target='_top'>More...</a></p>Similar proteinsⁱ